Victory Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Victory Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.22M	Buy	85,328 +31,077	+57%	+$345K	﹤0.01%	1814
2026 Q1	$506K	Buy	+54,251	New	+$489K	﹤0.01%	2033
2020 Q2	–	Sell	-520	Closed	-$2K	–	3317
2020 Q1	$2K	Buy	+520	New	+$2.88K	﹤0.01%	3542
2019 Q4	–	Sell	-288	Closed	-$3K	–	3309
2019 Q3	$3K	Buy	+288	New	+$5.21K	﹤0.01%	3583
2019 Q2	–	Sell	-2,605	Closed	-$70K	–	1866
2019 Q1	$70K	Sell	2,605 -12,482	-83%	-$459K	﹤0.01%	1684
2018 Q4	$430K	Buy	15,087 +4,936	+49%	+$200K	﹤0.01%	1401
2018 Q3	$780K	Sell	10,151 -516	-5%	-$40.3K	﹤0.01%	1316
2018 Q2	$1.11M	Sell	10,667 -567	-5%	-$55.4K	﹤0.01%	1232
2018 Q1	$1.42M	Buy	11,234 +1,104	+11%	+$107K	﹤0.01%	1162
2017 Q4	$656K	Buy	10,130 +2,132	+27%	+$129K	﹤0.01%	1296
2017 Q3	$473K	Sell	7,998 -163	-2%	-$8.68K	﹤0.01%	1331
2017 Q2	$522K	Sell	8,161 -93	-1%	-$6.13K	﹤0.01%	1306
2017 Q1	$647K	Buy	+8,254	New	+$501K	﹤0.01%	1256

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Victory Capital Management's ZVRA Position: Q2 2026 in Review

Victory Capital Management increased its Zevra Therapeutics (ZVRA) stake by 57% in Q2 2026, buying an estimated $345K and bringing the position to 85,328 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #1814.

Victory Capital Management first reported a position in ZVRA in Q1 2017 and has held it in 13 quarters since. The position peaked at $1.42M in Q1 2018. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Victory Capital Management held 85,328 shares of Zevra Therapeutics worth $1.22M as of Q2 2026.
Victory Capital Management bought 31,077 Zevra Therapeutics shares in Q2 2026, an estimated $345K.
Zevra Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1814 holding.
Victory Capital Management first reported a position in Zevra Therapeutics in Q1 2017 and has held it in 13 quarters since.
Victory Capital Management's Zevra Therapeutics position peaked at $1.42M in Q1 2018.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.